Drugs / Recaticimab
Trials 18 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06837077 | Mar → Jun 2025 overdue | hyperlipidemia | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05370950 | May → Dec 2022 | hyperlipidemia | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03634436 | Aug 2018 → May 2019 | hyperlipidemia | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03944109 | Jun 2019 → Dec 2020 | hyperlipidemia | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07062328 | Jul 2025 → Dec 2026 expected | biliary tract cancer | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06467617 | Aug 2024 → Aug 2026 overdue | non-small cell lung carcinoma | Beijing Chest Hospital, Capital Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT04455581 | Sep 2020 → Jun 2021 | familial hypercholesterolemia | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT07119918 | Sep 2025 → Dec 2029 expected | intracranial arteriosclerosis | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07002476 | Jun 2025 → Jun 2028 expected | ischemic stroke | Shanghai East Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT04885218 | Jul 2021 → May 2023 | hyperlipidemia, combined, 2, hyperlipoproteinemia | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04849000 | Apr 2021 → Jun 2022 | hyperlipidemia, hyperlipoproteinemia | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04844125 | Apr 2021 → Aug 2022 | hyperlipoproteinemia | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT07466251 | Sep 2026 → Dec 2028 expected | atherosclerosis, intracranial arteriosclerosis, ischemic stroke | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07674368 | Jul 2026 → Jul 2028 expected | non-small cell lung carcinoma | Hunan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07605130 | May 2026 → Sep 2028 expected | cognitive disorder, intracranial arteriosclerosis | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07373847 | Jan 2026 → Jun 2027 expected | psoriasis | Xiangya Hospital of Central South University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07290699 | Jan 2026 → Aug 2027 expected | ST-elevation myocardial infarction | Second Affiliated Hospital of Nanchang University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06902740 | Nov 2025 → Dec 2027 expected | cerebral artery stenosis, cerebral atherosclerosis | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07567326 Background | Jul 2026 → Dec 2028 expected | non-small cell lung carcinoma | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recaticimab | “This study aimed to assess the efficacy and safety of recaticimab, a new humanized anti-PCSK9 antibody capable of reducing LDL-C levels in patients with poorly controlled HeFH.” PMID 40911402 ↗ Oct 202513“Recaticimab (SHR-1209) is a humanized monoclonal antibody that binds to the proprotein convertase subtilisin/kexin type 9 (PCSK9) with high affinity.” PMID 40252193 ↗ Apr 2025 “Recaticimab (SHR-1209, a humanized monoclonal antibody against PCSK9) showed robust LDL-C reduction in healthy volunteers.” PMID 35039035 ↗ Jan 2022 |
| Known as | SHR-1209 | “Recaticimab (SHR-1209) is a humanized monoclonal antibody that binds to the proprotein convertase subtilisin/kexin type 9 (PCSK9) with high affinity.” PMID 40252193 ↗ Apr 20257“Recaticimab (SHR-1209, a humanized monoclonal antibody against PCSK9) showed robust LDL-C reduction in healthy volunteers.” PMID 35039035 ↗ Jan 2022 “Recaticimab (SHR-1209) injection, a fully human monoclonal antibody targeting PCSK9.” NCT07674368 ↗ |
| Action | Inhibit | “PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study.” PMID 35039035 ↗ Jan 2022 |
| Modality | Monoclonal antibody | “a humanized monoclonal antibody against PCSK9” PMID 35039035 ↗ Jan 2022 |
| Route | Subcutaneous | “Route of administration: subcutaneous” NCT03634436 ↗ |
| Target | PCSK9 | “a humanized monoclonal antibody against PCSK9” PMID 35039035 ↗ Jan 2022 |